Pennsylvania cannabis laws

Pennsylvania launched its medical cannabis program in 2016 under Act 16, also known as the Medical Marijuana Act. The law established one of the more restrictive medical frameworks in the country at the time, prohibiting smokable flower until 2018 and requiring physicians to register with the state before recommending cannabis. Since then, the program has expanded steadily in both patient enrollment and product availability, but adult-use legalization remains stalled in the legislature despite multiple proposals and bipartisan interest. As of mid-2026, Pennsylvania remains a medical-only state, creating a gray market fueled by proximity to neighboring states with recreational programs and a persistent illicit market that still captures an estimated 40 percent of total cannabis sales in the commonwealth.

The federal rescheduling of cannabis to Schedule III in early 2026 has had limited direct impact on Pennsylvania law. Medical dispensaries continue to operate under state regulations, and the rescheduling has not prompted any immediate legislative action on adult-use legalization. However, it has complicated tax treatment for Pennsylvania cannabis businesses, which now face questions about whether they can deduct ordinary business expenses on federal returns while still navigating state-level banking restrictions. The Pennsylvania Department of Revenue has issued limited guidance, and operators report confusion over whether Schedule III status changes their liability under the state's corporate net income tax.

Current Medical Cannabis Laws

Registered patients in Pennsylvania may possess up to a 30-day supply of medical cannabis as determined by their certifying physician. The state does not specify a hard weight limit, which has led to variability in what dispensaries will sell in a single transaction and occasional confusion during traffic stops. Patients must carry their state-issued medical marijuana ID card at all times when in possession of cannabis products. Flower, vaporizable concentrates, tinctures, topicals, and edibles are all available through the state's network of approximately 210 dispensary locations as of 2026. Smokable flower was legalized in 2018 after a court challenge, but public consumption of any form remains prohibited. Violations can result in fines and, in repeat cases, removal from the program.

Pennsylvania law offers limited workplace protections for medical cannabis patients. Employers may not discriminate against an employee solely on the basis of their status as a certified medical marijuana user, but they are not required to accommodate on-site use or impairment. Employers in safety-sensitive industries, including transportation, utilities, and construction, retain broad discretion to enforce zero-tolerance drug policies. Case law is still developing, but several Pennsylvania courts have sided with employers in wrongful termination cases where the employee tested positive for THC metabolites, even when the employee held a valid medical card and was not impaired on the job.

Medical Program Structure and Access

As of early 2026, Pennsylvania has approximately 470,000 active medical cannabis patients, representing roughly 3.6 percent of the state's population. Qualifying conditions include cancer, epilepsy, glaucoma, HIV/AIDS, post-traumatic stress disorder, inflammatory bowel disease, neuropathies, Parkinson's disease, multiple sclerosis, and chronic pain of specified origins. Anxiety disorders were added in 2019, which accounted for a significant jump in enrollment. The certification process requires an in-person or telehealth visit with a registered physician, followed by online registration with the Pennsylvania Department of Health and payment of a $50 annual fee, reduced to $0 for patients receiving certain state and federal assistance.

Dispensaries are operated by permit holders who also control cultivation and processing through vertically integrated licenses. The state originally issued 25 grower-processor permits and 50 dispensary permits in 2017, with additional rounds in subsequent years. Consolidation has been significant. Multi-state operators including Trulieve, Curaleaf, and Verano now control a substantial share of Pennsylvania's market, often through acquisitions of early permit holders who struggled with capital access and regulatory costs. Independent operators remain, but many report being squeezed by price competition and limited access to conventional banking.

Homegrow Prohibition

Pennsylvania does not permit home cultivation of cannabis for medical or any other purpose. All medical cannabis must be purchased from a licensed dispensary. Unlicensed cultivation remains a criminal offense, with penalties ranging from misdemeanors for small personal grows to felonies for larger operations. Possession of more than 30 grams of cannabis without a medical card is a misdemeanor punishable by up to 30 days in jail and a $500 fine. Over 30 grams triggers felony charges. Multiple adult-use legalization bills introduced in the legislature have included homegrow provisions, typically allowing four to six plants per household, but none have advanced to a floor vote.

Adult-Use Legalization Efforts

Governor Josh Shapiro, who took office in 2023, has expressed support for adult-use legalization and included projected cannabis tax revenue in budget proposals. However, the Republican-controlled state Senate has repeatedly blocked floor votes on legalization bills. The most recent effort, Senate Bill 846 introduced in 2025, proposed legal sales for adults 21 and older, a 20 percent excise tax on retail sales, automatic expungement of prior possession convictions, and the creation of social equity licenses for applicants from communities disproportionately affected by prohibition. The bill passed the House in late 2025 but stalled in Senate committee. Advocates point to polling showing consistent majority support for legalization among Pennsylvania voters, but rural and suburban Republican legislators remain opposed, citing concerns about youth access and impaired driving.

The stalemate has practical consequences. Thousands of Pennsylvanians drive to New Jersey, New York, or Ohio to purchase recreational cannabis legally, then return to Pennsylvania where possession without a medical card remains a crime. State police have conducted interdiction operations near border crossings, and some municipalities have increased enforcement. Meanwhile, illicit delivery services operating through social media and encrypted apps continue to thrive in Philadelphia, Pittsburgh, and college towns, often using CBD or hemp product storefronts as cover.

Social Equity and Expungement

Pennsylvania has no formal cannabis social equity program because it has not legalized adult use. However, several municipalities, including Philadelphia and Pittsburgh, have enacted decriminalization ordinances that reduce possession of small amounts to a summary offense similar to a traffic ticket. Philadelphia's policy, in effect since 2014, treats possession of 30 grams or less as a civil violation with a $25 fine, though police retain discretion to make arrests. Data from the Philadelphia district attorney's office shows that enforcement remains racially disproportionate, with Black residents receiving citations and arrests at rates three to four times higher than white residents, despite similar usage rates.

Expungement of prior cannabis convictions in Pennsylvania is limited. Individuals with summary convictions can petition for expungement after five years, but misdemeanor and felony convictions require a pardon from the governor, a process that typically takes years and offers no guarantee of approval. Advocates have pushed for automatic expungement tied to legalization, modeled on programs in Illinois and New Jersey, but without a legalization bill, the issue remains unresolved.

Federal Interactions and Cross-Border Issues

Medical cannabis patients in Pennsylvania are subject to federal firearms restrictions. Under federal law, any user of a controlled substance, even one legal under state law, is prohibited from purchasing or possessing firearms. ATF Form 4473, required for all gun purchases, explicitly asks whether the buyer is a user of marijuana. Pennsylvania State Police have declined to share medical cannabis registry data with federal authorities, but patients who answer the form truthfully cannot legally purchase firearms. Several advocacy groups have filed lawsuits challenging the policy, arguing that Schedule III reclassification undermines the rationale for the prohibition, but as of mid-2026, no court has ruled in favor of plaintiffs.

Driving under the influence of cannabis is prosecuted aggressively in Pennsylvania. The state has a zero-tolerance per se DUI law for Schedule I and II substances, meaning any detectable amount of THC in the blood can support a conviction, even if the driver is not impaired. The law was not updated after cannabis was moved to Schedule III, creating ambiguity about whether the per se standard still applies. Defense attorneys have begun challenging convictions on this basis, but appellate courts have not yet issued definitive rulings. Medical patients are not exempt from DUI laws, and several have been convicted despite having valid medical cards.

Industry Dynamics and Market Trends

Pennsylvania's medical cannabis market generated approximately $1.8 billion in sales in 2025, up from $1.6 billion the prior year. Growth has slowed compared to the 30 to 40 percent annual increases seen between 2019 and 2023, reflecting market maturation and increased competition from neighboring adult-use states. Average retail prices have declined, with an eighth of flower now typically priced between $35 and $50, down from $50 to $65 two years ago. Dispensaries have responded with loyalty programs, first-time patient discounts, and bulk purchase incentives.

Consolidation continues to reshape the industry. In 2024 and 2025, several mid-sized operators sold their licenses to multi-state operators, and at least two permit holders entered receivership. Smaller operators cite high regulatory compliance costs, limited access to capital, and price compression driven by larger competitors with national supply chains. Craft and artisanal brands exist but occupy a niche segment. Most patients prioritize price and potency over provenance, and dispensary staff report that house brands produced by vertically integrated operators dominate sales.

The illicit market remains entrenched. Law enforcement estimates that unlicensed sales still account for at least 40 percent of cannabis consumed in Pennsylvania, driven by lower prices, greater product variety including high-potency edibles not available in the medical program, and delivery convenience. Hemp-derived THC products, including delta-8 and delta-10 THC, are sold in gas stations, smoke shops, and online with minimal state oversight, further complicating enforcement and market dynamics. The Pennsylvania Department of Agriculture has issued warnings but has limited enforcement capacity, and many retailers continue to operate openly.